Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Elite Business Service, LLC (“EBSC Lending”), a leader in financing real estate throughout the United States and a specialized multifamily and seniors housing bridge lending platform, today announced the closing of a $13,000,000 in bridge financing for a 10-04-2025, 07:07

GPS Capital Markets Enters into Agreement to be Acquired by Corpay 20-06-2024, 11:49